These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11009049)

  • 1. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart.
    Jacobsen LV; Søgaard B; Riis A
    Eur J Clin Pharmacol; 2000 Aug; 56(5):399-403. PubMed ID: 11009049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes.
    Velojic-Golubovic M; Mikic D; Pesic M; Dimic D; Radenkovic S; Antic S
    J Endocrinol Invest; 2009 Jan; 32(1):23-7. PubMed ID: 19337010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
    Heise T; Hövelmann U; Brøndsted L; Adrian CL; Nosek L; Haahr H
    Diabetes Obes Metab; 2015 Jul; 17(7):682-8. PubMed ID: 25846340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.
    Thorisdottir RL; Parkner T; Chen JW; Ejskjaer N; Christiansen JS
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):216-21. PubMed ID: 19175369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with Type 1 diabetes: a randomized double-blinded crossover study.
    Chen JW; Lauritzen T; Christiansen JJ; Jensen LH; Clausen WH; Christiansen JS
    Diabet Med; 2005 Mar; 22(3):273-7. PubMed ID: 15717874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
    Heise T; Hövelmann U; Zijlstra E; Stender-Petersen K; Jacobsen JB; Haahr H
    Drugs Aging; 2017 Jan; 34(1):29-38. PubMed ID: 27873152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.
    Home PD; Barriocanal L; Lindholm A
    Eur J Clin Pharmacol; 1999 May; 55(3):199-203. PubMed ID: 10379635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes.
    Boehm BO; Vaz JA; Brøndsted L; Home PD
    Eur J Intern Med; 2004 Dec; 15(8):496-502. PubMed ID: 15668084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
    Heise T; Stender-Petersen K; Hövelmann U; Jacobsen JB; Nosek L; Zijlstra E; Haahr H
    Clin Pharmacokinet; 2017 Jun; 56(6):649-660. PubMed ID: 27878566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70.
    Ohira M; Endo K; Oyama T; Yamaguchi T; Ban N; Kawana H; Nagayama D; Nagumo A; Saiki A; Murano T; Watanabe H; Miyashita Y; Shirai K
    Metabolism; 2011 Jan; 60(1):78-85. PubMed ID: 20667560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
    Schmoelzer I; de Campo A; Pressl H; Stelzl H; Dittrich P; Oettl K; Wascher TC
    Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):176-81. PubMed ID: 15789278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study.
    Ma Z; Parkner T; Frystyk J; Laursen T; Lauritzen T; Christiansen JS
    Diabetes Technol Ther; 2012 Jul; 14(7):589-95. PubMed ID: 22519735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture.
    Weyer C; Heise T; Heinemann L
    Diabetes Care; 1997 Oct; 20(10):1612-4. PubMed ID: 9314644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers.
    Kaku K; Matsuda M; Urae A; Irie S
    Diabetes Res Clin Pract; 2000 Aug; 49(2-3):119-26. PubMed ID: 10963823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus.
    Haahr H; Pieber TR; Mathieu C; Gondolf T; Shiramoto M; Erichsen L; Heise T
    Clin Pharmacokinet; 2019 May; 58(5):639-649. PubMed ID: 30402720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions.
    Hövelmann U; Heise T; Nosek L; Sassenfeld B; Thomsen KMD; Haahr H
    Clin Drug Investig; 2017 May; 37(5):503-509. PubMed ID: 28185141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes.
    Mortensen HB; Lindholm A; Olsen BS; Hylleberg B
    Eur J Pediatr; 2000 Jul; 159(7):483-8. PubMed ID: 10923219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.